News

Techne (TECH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

All three major US stock indexes were up in late-morning trading Thursday, after Nvidia (NVDA) relea

Nvidia (NVDA) is just days away from releasing second quarter earnings results this Wednesday, August 26, as Wall Street expects quarterly revenue of $92 billion. The Morning Brief's Jake Conley sits down with Barron's senior markets analysis writer Paul La Monica and Infrastructure Capital Advisors CEO Jay Hatfield to discuss why excellent earnings may still not be enough to impress investors in this stage of the AI cycle.

The stock market still looks basically healthy, but the bond market is starting to show signs of stress.

Dow Jones futures: Crude oil continues to climb while bitcoin jumped again amid a weak dollar. Walmart earnings are in focus.

It’s all about retail earnings this week with Walmart, Home Depot, Target and Alibaba all set to report.

What a fantastic six months it’s been for Moderna. Shares of the company have skyrocketed 44.2%, hitting $63.36. This was partly due to its solid quarterly results, and the performance may have investors wondering how to approach the situation.

Net loss improved 5% on international partnerships and manufacturing gains.

Moby summary of Roivant Sciences Ltd.'s Q1 2026 earnings call

Roivant Sciences (NASDAQ:ROIV) said it expects a busy second half of 2026, with a potential launch of brepocitinib in dermatomyositis, several clinical readouts and additional regulatory discussions across its pipeline. Chief Executive Officer Matt Gline characterized the quarter as relatively quie

Roivant said its first quarter was relatively quiet operationally but positioned the company for a more active second half of 2026, with a potential launch of brepocitinib in dermatomyositis, multiple clinical readouts and further updates from Immunovant (NASDAQ:IMVT). Chief Executive Officer Matt

Roivant Sciences Ltd (ROIV) reports robust financials and key clinical milestones, including the brepocitinib launch and Moderna settlement, while navigating pipeline uncertainties.

Moby summary of Moderna, Inc.'s Q2 2026 earnings call

Moderna (NASDAQ:MRNA) reported second-quarter revenue of $145 million, exceeding the high end of its prior guidance range, while continuing to reduce costs and advance programs spanning respiratory vaccines, oncology and rare diseases. The company posted a net loss of $782 million, or $1.97 per sha

Biotechnology company Moderna (NASDAQ:MRNA) will be announcing earnings results this Friday before market hours. Here’s what investors should know.

Today Earnings (a.m.): Mastercard, Hershey, KKR, Yum Brands, Cigna, Regeneron, Valero Energy, Norwegian Cruise Line, Hyatt Hotels, Bristol-Myers Squibb, Altria, International Paper, SiriusXM, Blue Owl Capital Earnings (p.

Despite challenges in life sciences and European automotive sectors, Dassault Systemes SE (DASTF) reports robust revenue growth and strategic advancements in AI and cloud solutions.

Moderna is likely to announce its fiscal second-quarter earnings by the end of this month, and analysts expect its losses to narrow.

The past six months have been a windfall for Moderna’s shareholders. The company’s stock price has jumped 46.4%, hitting $62.97 per share. This was partly thanks to its solid quarterly results, and the run-up might have investors contemplating their next move.

Earnings season is winding down, but we still have a couple of big name companies reporting. This week we have Broadcom, Crowdstrike, Palo Alto Networks, Medtronic and Ciena Corp all reporting.

Roivant Sciences Ltd (ROIV) strengthens its financial position with a $2.25 billion Moderna settlement and prepares for key drug launches amidst mixed study results.

Roivant Sciences (NASDAQ:ROIV) executives used the company’s fourth-quarter earnings call to highlight new open-label data for IMVT-1402 in difficult-to-treat rheumatoid arthritis, upcoming pulmonary hypertension data for mosliciguat and continued preparation for a potential brepocitinib launch in d

On Wednesday, Roivant Sciences Ltd. (NASDAQ:ROIV) posted fourth-quarter adjusted earnings per share of $0.

The S&P 500 Index ($SPX ) (SPY ) on Monday closed up +0.19%, the Dow Jones Industrial Average ($DOWI ) (DIA ) closed up +0.19%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed up +0.29%. June E-mini S&P futures (ESM26 ) rose +0.18%, and June E-mini Nasdaq futures...